AstraZeneca's tremelimumab receives FDA approval to treat mesothelioma

British-Swedish drugmaker AstraZeneca has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its anti-CTLA-4 monoclonal antibody, tremelimumab to treat malignant mesothelioma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news